Adaptive Biotechnologies vs Arzeda
Adaptive Biotechnologies vs Arzeda, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Adaptive Biotechnologies is on 69/100 and Arzeda on 61/100.
Where each one leads
Adaptive Biotechnologies
- our overall score: 69/100 against 61/100
- domain rating: 61/100 against 39/100
- funding raised: $300M against $60.0M
Arzeda
- agent readiness: 64/100 against 39/100
At a glance
| Measure | Adaptive Biotechnologies | Arzeda |
|---|---|---|
| What it is | Leveraging the adaptive immune system to diagnose and treat disease. | Computational protein design company creating novel enzymes and proteins using AI and physics-based modeling. |
| Category | Biotech, HealthTech, Genomics, Drug Discovery | Biotech, AI-Driven Protein Design, Computational Biology, Enzyme Engineering |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | services | platform | Software |
| Founded | 2009 | 2008 |
| Headquarters | Seattle, United States | Seattle, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Adaptive Biotechnologies | Arzeda |
|---|---|---|
| Employees | Not published | 74 |
| Headcount growthLast 12 months | Not published | +29.2% |
| Total funding | $300M | $60.0M |
| Latest round | Series D | Series B |
| LinkedIn followers | Not published | 8,740 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Adaptive Biotechnologies | Arzeda |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 69/100 | 61/100 |
| Traction | Not published | 58/100 |
| Team | Not published | 70/100 |
| Community | Not published | 15/100 |
| Search visibility | Not published | 23/100 |
| Quality | Not published | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (39/100) | C (64/100) |
| Domain ratingLink authority, 0-100 | 61/100 | 39/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Adaptive Biotechnologies | Arzeda |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CMS | WordPress | Ghost |
| Frameworks | Jquery | Angular |
| Analytics | Google Tag Manager | Not detected |
Adaptive Biotechnologies vs Arzeda: common questions
Which is better, Adaptive Biotechnologies or Arzeda?
On our 0-100 score Adaptive Biotechnologies rates higher (69/100 against 61/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Adaptive Biotechnologies and Arzeda compare on the numbers?
Adaptive Biotechnologies leads on our overall score (69/100 against 61/100), domain rating (61/100 against 39/100), funding raised ($300M against $60.0M). Arzeda leads on agent readiness (64/100 against 39/100).
Read the full Adaptive Biotechnologies review and pricing or the Arzeda review and pricing. You can also browse other Adaptive Biotechnologies alternatives we track.